AzTrials
AzTrials

Migraine ProphylaxisPhase 2NCT05846373

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

A Phase 2 study testing Nicotinic Acid 500 MG Extended Release Oral Tablet and Nicotinic Acid 1000 MG Extended Release Oral Tablet in people with Migraine Prophylaxis, run by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a prospective single center, randomized, double-blind, 3 arm placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive Nicotinic Acid Extended-release tablet 500 mg or 1000 mg or placebo for 12 weeks. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Migraine Prophylaxis
What is being tested?
Nicotinic Acid 500 MG Extended Release Oral Tablet and Nicotinic Acid 1000 MG Extended Release Oral Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
58 participants
Where
1 siteBangladesh
Study dates
25 Nov 2022to 10 Jan 2024
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients suffering from migraine with or without aura according to International ICHD 3 criteria
  • Patients with 4-15 qualified migraine attacks per month during the four weeks of the Baseline Phase
  • History of headache for at least 1 year
  • Age at onset of migraine should be less than 50 years
  • Headache intensity: Moderate to severe (Visual analogue scale score at least 3)
  • Consuming one β Blocker as prophylaxis

Who cannot join

  • Pregnancy and lactation
  • Known case of any hepatic, psychiatric diseases except depression, diabetes mellitus (DM), gout, peptic ulcer disease
  • Known hypersensitivity to niacin
  • Consumption of certain drugs Lipid lowering agents Antiplatelet and Anticoagulants Antihypertensive medications Alcohol or other abusive drugs
  • Plasma Nicotinic acid level > 8.45 µg/mL

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • BSMMU

    Dhaka, 1000

Other trials in Bangladesh

About this study

Official title: Effect of Nicotinic Acid as add-on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine: A Randomized, Double-blind, Placebo-controlled Trial

This is a prospective single center, randomized, double-blind, 3 arm placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive Nicotinic Acid Extended-release tablet 500 mg or 1000 mg or placebo for 12 weeks. The safety and efficacy outcome measures will be assessed at baseline and 12 weeks.

Read the detailed description

Migraine is "a common episodic neurological disorder with complex pathophysiology that manifests as recurrent attacks of typically throbbing and unilateral, often severe headache with certain associated features such as nausea, phonophobia, and photophobia". Worldwide, estimated prevalence was 13.8% to 15%. Quality of life of a migraine patient is extremely low and migraine badly hampers one's physical, emotional, and social efficiency and disrupt familial, social and professional relationships. Diagnosis is solely clinical depending on characteristics of headache and associated symptoms. Neuroimaging can be done only when exclusion of another cause of headache is needed.

Exact etiology and pathophysiology of migraine is unknown and multifactorial. There are several hypotheses of migraine pain generation. Local dilatation of intracranial and extracerebral vessels activate trigeminal nerve surrounding cerebral and meningeal vasculature. Migraine pain starts from the activation of trigeminovascular system. Afferent fibers innervating cerebral and meningeal vessels project to central nervous system and releases vasoactive peptides and inflammatory mediators. Some important mediators like Calcitonin gene related peptide (CGRP), NO, Substance P play role in inflammation and vasodilatation. Then sensitization and discharge of thalamic neuron and subsequent projection to sensory cortical neurons occurs. Thus, pain perception is received in migraine.

In studies, elevated levels of C reactive protein (CRP) and Transforming growth factor β (TGF-β) provides evidence of neuroinflammation. In migraine, impairment of cerebral mitochondrial energy metabolism and oxidative stress occurs. As a result, abnormalities in cerebral vasculature results in Cortical Spreading Depression (CSD).

Niacin, which is known as nicotinic acid or Vitamin B3 is the precursor of Nicotinamide Adenine Dinucleotide (NAD) or Nicotinamide Adenine Dinucleotide Phosphate (NADP). From dietary tryptophan, through kynurenine pathway, NAD is produced, and rest 1% tryptophan is catabolized to form serotonin (5- hydroxytryptamine/ 5-HT). Migraine is a serotonin deficient condition. It has been estimated that, dietary intake of Niacin is low in migraine patients.

Niacin supplementation provides enough NAD to inhibit Kynurenine pathway and accelerate production of 5-HT from tryptophan. Serotonin acting on 5-HT1 receptor, causes vasoconstriction. It may activate nerve endings in cerebral microcirculation and sensitize them to vasodilatory kinins. Serotonin also inhibits synthesis, release of NO, glutamate, Calcitonin gene-related peptide (CGRP). As a result, inhibition of afferent pain transmission and prevention of neuroinflammation occurs. Niacin also reduces inflammation evidenced by decrease level of pro inflammatory cytokines like IL-6, IL-1β, TNF α, high-sensitivity C-reactive protein (hs-CRP). Increasing level of Niacin also improves brain energy deficiency, and has potent antioxidant properties, which may be helpful in migraine prevention. However, more prospective investigations are necessary to validate niacin's preventive effect on migraine.

Being tested
Nicotinic Acid 500 MG Extended Release Oral Tablet, Nicotinic Acid 1000 MG Extended Release Oral Tablet, Placebo

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nicotinic Acid 500 MG Extended Release Oral TabletDrug

    Also called Niacin

    Nicotinic acid 500 mg for 12 weeks

  • Nicotinic Acid 1000 MG Extended Release Oral TabletDrug

    Also called Niacin

    Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week

  • PlaceboOther

    Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week

Study groups in NCT05846373
Study groupRoleWhat they receive
Nicotinic Acid Extended-release tablet 500 mg armActive comparatorThis arm includes 22 Migraine patients receiving beta blocker
Receives: Drug: Nicotinic Acid 500 MG Extended Release Oral Tablet
Nicotinic Acid Extended-release tablet 1000 mg armActive comparatorThis arm includes 22 Migraine patients receiving beta blocker
Receives: Drug: Nicotinic Acid 1000 MG Extended Release Oral Tablet
Control armPlacebo comparatorThis arm includes 22 Migraine patients receiving beta blocker
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Migraine days/4 weeks

    Mean change from baseline in migraine days/4 weeks from baseline to weeks 9-12

    Measured: Baseline to week 12

Secondary outcomes (4)
  1. Visual Analogue Scale (VAS) Score

    Changes of mean VAS Score from baseline to weeks 9 - 12. The average migraine attack severity will be calculated using the sum of the severity of migraine attacks, divided by the number of qualified migraine attacks. The scale of severity for each migraine attack ranges from 0 to 10, with higher scores indicating increased migraine severity.

    Measured: Baseline to week 12

  2. Migraine Specific Quality of Life questionnaire version 2.1 (MSQ V. 2.1)

    Changes of mean MSQ V. 2.1 score from baseline to weeks 9 -12. The MSQ V. 2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains; Role function restrictive (RR), Role function preventive (RP), Emotional function (EF) consist of 7, 4 and 3 items respectively. Score ranges from 0 - 100 in each domain. The higher scores indicate better outcome.

    Measured: Baseline to week 12

  3. Frequency of use of acute migraine specific medications in the last 4 weeks

    Changes in number of days receiving migraine aborting medication/(s) from baseline to weeks 9-12

    Measured: Baseline to week 12

  4. hs-CRP

    Change in hs-CRP level from baseline to week 12

    Measured: Baseline to week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2023
  2. Study start25 Nov 2022
  3. Primary completion10 Jan 2024
  4. Study completion10 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
58 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05846373
Sponsor's protocol ID
BSMMU/2022/11548
Status last verified
Jan 2024
First submitted
26 Apr 2023
Last updated
18 Nov 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Nicotinic Acid 500 MG Extended Release Oral Tablet and Nicotinic Acid 1000 MG Extended Release Oral Tablet in people with Migraine Prophylaxis, run by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Migraine days/4 weeks (time frame: Baseline to week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in